AIM movers: Versarien pipeline and Good Energy solar acquisition

4

EnergyPathways (LON: EPP) rose a further 31.1% to 2.95p following yesterday’s announcement it has secured a £5.1m loan facility for the Marram Energy Storage Hub (MESH) clean energy storage project and today’s launch of a new interactive corporate website. EnergyPathways believes that the project should reach final investment decision by the end of 2025.

Graphene technology developer Versarien (VRS) has an opportunity pipeline of £4.7m. Earlier in the week it signed an agreement with Balfour Beatty to develop 3D-printable mortars for civil construction. It will formulate three types of mortar. This follows the disposal of AAC Cryoma for £550,000 payable in 15 instalments. The share price is 11% higher at 0.0605p.

MicroSalt (LON: SALT) has expanded its international patent portfolio. The latest low sodium salt patents are in China, Mexico and Australia. The share price increased 5.88% to 36p.

Good Energy (LON: GOOD) has acquired Lincolnshire-based solar installer Amelio Solar for an initial £5.5m. This broadens the geographic spread of the energy services division. The focus of the business is the education and public sector. In 2023, revenues were £7m and pre-tax profit is £1.4m. However, there have been lower levels of activity in Good Energy’s existing installation business. Canaccord Genuity has left its 2024 pre-tax profit forecast of £6.7m and it has only edged up its 2025 forecast from £10.7m to £10.8m because the weakness offsets the additional contribution. The share price improved 5.77% to 275p.

FALLERS

RBG Holdings (LON: RBGP) executive director Tania MacLeod stepped down from the board yesterday afternoon, although she is staying as a director of subsidiaries and as senior partner of law firm Rosenblatt. Delays in projects have hit the prospects of the legal services company and Singer has withdrawn forecasts. The share price slumped a further 29.2% to 2.125p and is down nearly two-thirds on the week.

Woodbois (LON: WBI) has raised a further £1m via a subscription at 0.28p/share. The share price slipped 22.2% to 0.315p. The timber company will use the cash to fund exports and provide working capital. The cash is provided by Axis Capital Markets clients.  

David Crichton-Watt has increased his stake in Steppe Cement (LON: STCM) from 16.97% to 17.3%. The share price dipped 5.36% to 13.25p.

Abingdon Health (LON: ABDX) is reporting results for the year to June 2024 on Tuesday 8 October. The share price declined 2.7% to 9p.

Hummingbird Resources – Big Changes Underway Could Prove Transformational For This Gold Producer, Broker’s Speculative Buy Price Aim Is 17p, For Shares Now Just 6.7p 

Generally, news that a company is about to undertake an operational, financial and strategic review is not seen as a good omen. 

So what is going to happen at Hummingbird Resources (LON:HUM) – which late last week announced that it had just received another $20m loan from CIG SA, its largest shareholder? 

It is also about to launch a comprehensive group-wide review, aimed at delivering operational improvements and realising the company’s potential as a multi-asset, multi-jurisdictional gold producer. 

The Business 

Hummingbird Resources is a leading multi-asset, multi-jurisdiction gold producing company, a member of the World Gold Council and founding member of Single Mine Origin. 

The £54m capitalised group’s stated vision is to continue to grow its asset base, producing profitable ounces. 

It currently has two core gold projects, the operational Yanfolila Gold Mine in Mali, and the Kouroussa Gold Mine in Guinea, which will more than double current gold production once at commercial production.  

The company also has a controlling interest in the Dugbe Gold Project in Liberia that is being developed by joint venture partners, Pasofino Gold Limited.  

The final feasibility results on Dugbe showcase 2.76Moz in Reserves and strong economics such as a 3.5-year capex payback period once in production, and a 14-year life of mine at a low AISC profile.  

However, it is believed that the company is looking at potentially divesting its non-core assets including the Dugbe Gold Project in Liberia, where it holds a 53% stake in Pasofino, which is an owner of Dugbe. 

Hummingbird has already engaged in informal, non-binding discussions with several parties regarding the sale of certain assets including the Dugbe Gold Project in Liberia. 

The Loan Facility 

The group secured a loan facility of $30m from CIG SA, including that new $20m loan and a consolidation of a previously announced $10m short-term loan.  

The loan, which is unsecured, carries a 14% interest with an initial maturity of December 2024.  

The company anticipates transitioning this loan into a longer term fixed-rate, gold-linked loan note, details of which are currently being finalised.  

There are several opportunities to increase the size of the ‘Gold Loan’ due to additional interest, with the company making further updates in due course. 

The company is bringing in third-party consultants to review its corporate structure with a view to identify cost efficiencies and improvements in governance including Board and management changes.  

Management Comment 

Chairman Dan Betts stated that: 

“As we continue to navigate the challenges at Kouroussa, we are committed to taking decisive actions to strengthen Hummingbird’s operational foundation and unlock its full potential as a multi-asset, multi-jurisdictional gold producer.  

The Group-wide review is an important step towards optimising our production capabilities and enhancing shareholder value. 

While Kouroussa’s ramp-up has been affected by various unforeseen factors, we are focused on reaching commercial production in Q4-2024.  

Whilst we are confident of commercial production in the coming quarter, it is dependent on us and our partners delivering meeting our production plan and expectations.    

Our focus remains on sustainable growth, securing additional financing, and completing leadership transitions to ensure the successful delivery of our ambitious growth objectives to deliver 200 Koz pa of gold. 

After 17 years of building Hummingbird from a grassroots exploration company to a gold producer with an annual run rate exceeding 200,000 ounces, I believe the time is right for a new leadership team to guide the Company through its next phase.  

I am proud of what we have achieved and will continue to focus on strategic opportunities and key relationships as Chairman of Hummingbird.” 

Analyst Views 

Tim Huff and Alex Bedwany, at Canaccord Genuity Capital Markets, now have a Speculative Buy Price Objective of 17p on the group’s shares, based on a 50/50 weighting of their longer term NPV (at 1.0x) of 28p, and their near-term EV/EBITDA weighted value (at 4.5x) of 6p. 

Prior to the results of the Review, the analysts have estimates out for the current year to end-December to show an EBITDA of $38.5m ($11.2m), leading up to a massive $206.0m EBITDA next year, worth $11.92 per share in earnings. 

In My View 

The company believes that this latest support and new Review will help to capitalise on the strong platform that it has built to date, while enabling it to evolve into a robust mid-tier gold mining company. 

Four years ago, the shares were up to 43p and have been down to a low of just 4p since then. 

The question now is whether the shares, at just 6.7p, are ‘option money’ on some very big returns in due course? 

Watches of Switzerland snaps up media platform Hodinkee

The Watches of Switzerland Group has announced the acquisition of Hodinkee, the world’s foremost digital platform for horology enthusiasts.

Founded in 2008, New York-based Hodinkee has become the global epicentre for luxury timepiece aficionados. The platform boasts an impressive reach, with 22.2 million annual unique visitors and a social media following exceeding one million. Its offerings span digital, print, and video content, alongside exclusive watch collaborations and specialised insurance services.

This strategic acquisition aligns perfectly with WOSG’s Long Range Plan, which emphasises leveraging growth opportunities and expanding online sector leadership. The integration of Hodinkee’s commercial activities into WOSG’s operations is set to provide the group with access to a highly engaged, captive audience of luxury watch enthusiasts.

The acquisition, funded through existing financing facilities, is not expected to significantly impact WOSG’s leverage position. It marks a significant step in the Group’s strategy to remain at the forefront of the luxury industry, particularly in the rapidly growing US market.

With this latest addition, the Watches of Switzerland Group’s has an impressive portfolio of luxury watch retail and media including Watches of Switzerland, Mappin & Webb, Goldsmiths, Mayors, Betteridge, Hodinkee, and Analog:Shift.

“I am thrilled to have Hodinkee join the Watches of Switzerland family. We have been avid followers of Hodinkee for many years and have long-respected Ben and his team’s success in creating the undisputed destination for luxury watch enthusiasts,” said Brian Duffy, CEO of the Watches of Switzerland Group.

“With the support of the wider Group, we will enable Ben and his best-in-class editorial team to keep doing what Hodinkee does best: further expanding its passionate and loyal community by being the most authentic and authoritative voice on the industry.

“Our strategy at WOSG is focused on staying at the forefront of the luxury industry, aligning with brands which inspire us and whose partnership offers a mutually beneficial outcome. The acquisition of Hodinkee directly supports our ecommerce business, driving traffic and brand awareness across our markets, and particularly in the US, further enhancing our sector leadership online.”

AIM movers: EnergyPathways loan facility and ex-dividends

17

EnergyPathways (LON: EPP) has secured a £5.1m loan facility for the Marram Energy Storage Hub (MESH) clean energy storage project. This should enable the project to reach final investment decision by the end of 2025. Global Green Asset Financing is providing the facility and has to raise additional cash via a placing of loan notes to provide it. The minimum commitment for the facility, which lasts three-years, is £2.55m and the interest rate is 12.5%/year. The share price jumped 41.9% to 2.2p.

Mkango Resources (LON: MKA) rare earths recycling business has been awarded £220,000 of grants through a $15m investment programme managed by Innovate UK. The cash will be used to advance medium-loop and long-loop rare earth magnet recycling routes. Mkango owns 80% of this business and CoTec the other 20%. The share price improved 4.76% to 5.5p.

EMV Capital (LON: EMVC) director Jonathan Robinson bought 25,000 shares at 52p each following the interim results announcement of the company that was previously known as NetScientific. Total assets under management reached £106.7m following the addition of the Martlet Capital portfolio. Net assets edged up from £17.1m to £18.5m. Nasdaq-listed investee company PDS Biotech announced a 36-month survival rate of 84.4% in locally advanced cervical cancer patients treated with the company’s lead target drug Versamune HPV and Chemoradiation. The share price recovered 3.88% to 53.5p.

Panmure Liberum has moved from hold to buy for online fashion retailer boohoo (LON: BOO) and has set a price target of 35p. The share price rose 3.85% to 31.3p.

FALLERS

Premier African Minerals (LON: PREM) has raised £550,000 at 0.0315p and this will be spent on operational activities at the Zulu lithium and tantalum project. Management is hopeful that it will soon resolve problems with the processing facilities. The company says that options for the Zulu project including selling it or part of it. The share price declined 12.2% to 0.0325p.

Metals One (LON: MET1) has identified high-grade intersections of nickel, copper, cobalt and zinc in re-assayed cores from past drilling on the black schist project in Finland. The current resource is 57.1mt of nickel, copper, cobalt and zinc. There is potential for a larger, shallow mineral resource. The share price fell 5% to 0.475p.

Xtellus Capital Partners has reduced its stake in Serinus Energy (LON: SENX) from 20% to 19.15%. The share price is 4.94% lower at 3.85p.

Wyloo Consolidated Investments has raised its shareholding in Greatland Gold (LON: GGP) from 8.6% to 10.6%. The share price dipped 4.76% to 6p.

Ex-dividends

Arcontech (LON: ARC) is paying a final dividend of 3.75p/share and the share price is 3.5p lower at 119.5p.

Andrews Sykes (LON: ASY) is paying an interim dividend of 11.9p/share and the share price fell 5p to 535p.

Facilities by ADF (LON: ADF) is paying an interim dividend of 0.5p/share and the share price slipped 1.3p to 51p.

Frenkel Topping (LON: FEN) is paying a final dividend of 1.38p/share and the share price rose 0.5p to 44p.

Franchise Brands (LON: FRAN) is paying an interim dividend of 1.1p/share and the share price dipped 0.5p to 145.5p.

HSS Hire (LON: HSS) is paying an interim dividend of 0.18p/share and the share price declined 0.21p to 6.61p.

Ingenta (LON: ING) is paying an interim dividend of 1.5p/share and the share price is down 1p to 90.5p.

Johnson Service Group (LON: JSG) is paying an interim dividend of 1.3p/share and the share price slid 1.2p to 155p.

Litigation Capital Management (LON: LIT) is paying a final dividend of 1.25p/share and the share price increased 1.75p to 102.25p.

Learning Technologies Group (LON: LTG) is paying an interim dividend of 0.45p/share and the share price is 0.6p lower at 93.4p.

Mortgage Advice Bureau (LON: MAB1) is paying an interim dividend of 13.4p/share and the share price slid 9p to 677p.

Mercia Asset Management (LON: MERC) is paying a final dividend of 0.55p/share and the share price is unchanged at 32p.

Personal Group Holdings (LON: PGH) is paying an interim dividend of 6.5p/share and the share price declined 4p to 168p.

Real Estate Investors (LON: RLE) is paying a dividend of 0.5p/share and the share price is unchanged at 33p.

Skillcast (LON: SKL) is paying an interim dividend of 0.17p/share and the share price is unchanged at 46.5p.

Van Elle (LON: VANL) is paying a final dividend of 0.8p/share and the share price declined 0.5p to 40p.

FTSE 100 taken higher by Tesco and the housebuilders

There was a mild bout of optimism in UK equities on Thursday despite ongoing tension in the Middle East as the housebuilders and Tesco outperformed and helped the FTSE 100 higher.

Tensions in the Middle East remained a major concern, although they took a back seat to news closer to home on Thursday.

Positivity emanating from an upbeat Zoopla report on the UK property market and strong corporate results from Tesco offset weakness in miners as the index gained 0.3%.

After announcing rising revenues and profits amid action on lowering costs, Tesco was the top riser as investors cheered a 15% jump in operating profit.

“For a company in such a competitive market and with an already dominant market position to be taking share is quite the feat and that’s something Tesco has achieved in the first half of its financial year,” said AJ Bell investment director Russ Mould.

“The supermarket also demonstrated its confidence in its future prospects heading into the crucial Christmas trading period with a healthy increase in the dividend. This is underpinned by strong cash generation, which is also enabling Tesco to invest in the business and compete effectively on price.

“Its focus on value is clearly getting customers through the doors and the tills ringing and, alongside measures like its Clubcard discounted prices, should help to engender loyalty. A fairly astonishing 23 million households now have a Clubcard membership.”

The latest Zoopla House Price Index showing transaction activity increase 25% has been taken well by investor who saw a chance to jump into the housebuilding sector.

Persimmon shares added 3% and Barratts rose 2% after Zoopla’s revealed an improving environment for housebuilders and a 1% increase in average prices over the past year.

“The number of sales agreed is now 25% higher than a year ago as households that have held off making moving decisions over the last 2 years return to the market,” Zoopla wrote in their report.

“Sales are up by over 10% across the UK, and more than 30% across the East Midlands and North East.”

New AIM admission: Optima Health shares slip despite strong market position

Optima Health has demerged from Marlowe (LON: MRL) on the basis of one share for each Marlowe share held. The company is the market leader in the UK occupational health sector with a share of around 10%. This has been achieved through investment in technology.

The Optima Health business was originally acquired by Marlowe in early 2022 and integrated with its existing operations in the sector. Long-term contracts help to make the business more predictable. There are more than 2,000 clients, although one accounts for more than 10% of revenues.  

Optima Health is focused on the UK. Th...

Tesco fights off discounters to increase market share as profits jump

There is an awful lot to like about Tesco’s half-year update. The company is growing revenues, winning market share and importantly, increasing operating margins.

Investors will also be delighted with the 15% increase in operating profit for the period.

UK & ROI adjusted operating margins were 4.7% compared to 4.2% for the last full year period. The increase in operating margins is interesting, given the supermarket is locked in a bitter price war with the discounters to win over cost-conscious consumers.

“We have lowered prices on thousands of lines, launched or improved over 860 products in partnership with our suppliers and growers, and our customer satisfaction scores continue to improve across a broad range of measures,” said Ken Murphy, Chief Executive.

“The combination of price, quality and innovation means we are as competitive as we have ever been, and we have been the cheapest full-line grocer for nearly two years.”

Action on pricing has resulted in Tesco growing its market share and cementing its place as the UK’s leading supermarket. Tesco’s market share hit 27.8% in the period, Tesco’s highest market share level since January 2022.

“Tesco’s excellent 2024 performance is reflected in this morning’s results as the UK’s largest supermarket reported a further increase in profits as their shares surged to an eleven-year high,” said Mark Crouch, market analyst at investment platform eToro.

“Throughout a period in which supermarkets have faced a whole host of headwinds, from a global pandemic to high inflation and a cost-of-living crisis, Tesco has not only maintained their market share but increased it to the highest point in almost three years. And despite the rise of budget supermarket chains, who have managed to wrestle away market share from other big names in the sector, Tesco has not been one of them. 

“There are several reasons for this. Food sales growth has been an area where Tesco is rarely beaten, offering a larger and wider variety of products to their customers. Price-matching and Tesco’s Club Card loyalty program, which has grown to over 22 million members and counting, have also been a resounding success.”

Tesco shares were 2% higher at the time of writing.

British Land makes big bet on retail parks

British Land has made a bold move to increase its exposure time UK retail parks by raising £300m to help fund the acquisition of seven sites.

The high street is dead, and it has been for some time. That said, out of town retail parks are proving to be increasingly popular.

The mix of shopping and leisure experiences in retail parks that consumers can easily drive to have stolen the footfall of UK shoppers and British Land is realigning its portfolio accordingly.

The seven sites will considerably increase British Land’s weighting towards retail and generate the Real Estate Investment Trust 6.7% in net yields initially.

British Land raised cash for the acquisitions by way of a placing at a 3.6% discount to yesterday’s closing price. 

“British Land has raised around £301mn from investors to help fund the purchase of seven retail parks for £441mn. Sites like this now make up around 32% of the entire portfolio, up from 18% just 18 months ago, and are core to British Land’s expansion strategy,” said Matt Britzman, senior equity analyst, Hargreaves Lansdown.

“There are two key takeaways here. The first is that the ongoing consumer shift from the high street to out-of-town retail locations is clearly a trend that companies are trying to take advantage of – we heard from Greggs earlier this week who is taking this approach for new store locations. The second is that the large-scale acquisition market for property giants is back open, after a period of low activity.”

Avacta Group – Exploring NASDAQ Dual-Listing And Divesting Its Diagnostics Division, Analyst Has 188p Valuation, Shares Now 45.5p 

On Wednesday 30th October, Avacta Group (LON:AVCT), the cancer treatments and diagnostics life sciences business, will be presenting a live Research & Development Spotlight entitled Next Generation of pre|CISION Medicines. 

It is expected that there will be keen investor interest to hear what the group has to say about its pre|CISION platform. 

The Business 

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. 

It has two main segments: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division focused on supporting healthcare professionals. 

Avacta Therapeutics: which is the clinical stage oncology biotech division that is harnessing the proprietary pre|CISION platform technology to develop novel, highly targeted cancer drugs. 

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues.  

Avacta Diagnostics: which focuses on supporting healthcare professionals and broadening access to diagnostics, has two business units – Launch Diagnostics and Coris Bioconcept.  

Launch Diagnostics is a well-established sales channels in the professional, centralised hospital laboratory testing market in the UK and France.  

Coris, based in Gembloux, Belgium, develops, manufactures and markets rapid diagnostic test kits, mainly lateral flow tests, for use by healthcare professionals.  

In the highly competitive diagnostics market, Avacta’s proprietary Affimer® platform has the potential to provide differentiated immunodiagnostic products to gain competitive advantage and grow market share. 

This Week’s Interim Results 

Last Monday morning the group reported its Interim Results for the six months to end-June, showing much in line with expectations, with revenues off slightly at £11.3m (£11.9m) and running at a first-half loss of £12.5m (£11.5m). 

The Diagnostics division revenues advanced to £11.2m (£9.9m), however, it must be noted that the company has started the process to divest this side of the business, in order to maximise value for shareholders, while ensuring its focus as a therapeutics-focused company and support its appeal to specialist international investors. 

After the £31.1m cash raise in March this year, the group ended the period with £32.5m cash and cash equivalents, against £26.6m at the same time last year.  

The first six months of the year saw a number of managerial and operational changes, while its financial position remains in line with the Board’s expectations. 

Management Comments 

New Chairman Shaun Chilton stated that: 

“Over the four months since Chris Coughlin’s and my appointments, we have made significant progress on key strategic priorities.  

Alongside the Board and wider team, we have carried out a detailed review of all the Group’s operations and financials with a focus on prioritizing further investments in therapeutics, including the acceleration of the AVA6000 clinical trial enrolment.   

We are very encouraged by the potential of the innovative medicines in the Avacta pipeline which we plan to present at our live R&D Spotlight in October focusing on the Next Generation of thepre|CISION™platform. 

We have commenced a process to divest the Diagnostics Division and have started to receive indicative offers. 

Our longer-term financing strategy is being formulated and includes a potential dual listing of the Company on NASDAQ, which the Board sees as a key strategic option for the Company.” 

Avacta aims to leverage its proprietary pre|CISION™ platform to develop innovative oncology therapies that make a significant difference to cancer patients’ treatment experience and outcomes. 

The pre|CISION™ platform has the potential to enable patients to achieve improved outcomes with fewer side effects by leveraging the tumor specific enzyme Fibroblast Activation Protein (FAP) to protect normal tissues from toxic drugs. 

The group is poised to move into the next stage of development, implementing these findings of this drug release mechanism across our innovative pipeline. 

New CEO Christina Coughlin, MD, PhD, stated that: 

“We are seeing notably positive progress on our drug development candidate AVA6000 with the completion of the Phase 1a trial with no maximum tolerated dose and opening of the RDE expansion.   

This novel peptide drug conjugatecontinues to demonstrate a highly favourable tolerability profile and robust preliminary signs of efficacy, with several durable responses, as it moves through clinical development. 

The AVA6000 data in the clinic has led to a growing confidence in the pre|CISION™platform and its potential for patients.  

Our next generation programs will leverage the pre|CISION™ platform as a foundation for other tumor-specific warhead delivery systems. 

This platform will underpin our wider clinical strategy and our ambition of bringing these novel cancer medicines closer to patients and delivering value for shareholders.”  

Analyst Views 

At Trinity Delta, its analysts Lala Gregorek and Philippa Gardner consider that Avacta is transitioning into a developer of innovative highly targeted specialist oncology products.  

They state that once the Diagnostics division has been divested, Avacta will become a fully focused biotech company.  

That is an important element of the strategy to broaden Avacta’s appeal to specialist healthcare investors via a potential additional listing on NASDAQ, securing sustainable funding for further pipeline development.  

Trinity Delta concludes by noting that  

“pending the October R&D event in London we maintain our Avacta valuation of £675m, equivalent to 188p/share.” 

In My View 

There is a lot going on within this £161m capitalised group.  

The recent corporate shake-up appears to have been initially beneficial, and if the divestment goes ahead, and a NASDAQ quote is achieved, this group could well be significantly improving its 45.5p share price within months. 

FTSE 100 clings on to gains amid Middle East tensions

The FTSE 100 was higher on Wednesday despite major escalations in the Middle East overnight as commodities provided a safe haven for investors.

Iran launched a barrage of missiles at Israel while Israel moved more troops into Lebanon overnight sparking concerns of all-out war in the region.

However, the dynamics of the FTSE 100 index and its leaning towards safe havens meant London’s leading found support as investors flocked to commodities companies.

“As Iran’s cruise missile attack on Israel and fresh strikes on Hezbollah in Lebanon have unnerved investors,” said Susannah Streeter, head of money and markets, Hargreaves Lansdown.

“The uncertainty has made safe-haven assets like gold more popular, with demand for the precious metal ticking up close to record levels, as violence spills further across the Middle East, briefly climbing above $2,670 an ounce. Already sought after, amid concerns that inflationary pressures would persist, fresh geopolitical fracture has increased demand for gold.  The dollar has steadied after gaining ground and US Treasuries proved more popular, indicated by falling yields, as investors have sought out trusted shelters amid the widening conflict.

Oil prices are climbing, with Brent Crude approaching $75 a barrel, as supply concerns swirl again, sparked by heightened aggression. These worries are being mitigated by expectations that Saudi Arabia will turn on the taps more fully, and lower demand from China, but upwards pressure is likely to continue while uncertainty reigns about just how far conflict will spread.”

Rising oil prices helped lift oil majors BP and Shell on Wednesday with gains of 2.1% and 2.5% respectively.

Prudential was the top riser as optimism around China was untouched by developments in the Middle East. China has ramped up its efforts to stimulate the economy, paying particular attention to the financial sector. Prudential shares were 3% higher at the time of writing.

JD Sports was the top faller amid ongoing worries about Nike. Despite JD reaffirming guidance for the year, investors were more concerned with Nike’s ongoing uncertainty given the fact around half of JD’s sales around from Nike products.

“JD Sports has a multi-brand strategy and is continuing to roll out new stores and make acquisitions globally, yet Nike’s warning that the festive period may be littered with discounts could well have had some contagion effect,” said Adam Vettese, market analyst at investment platform eToro.

“Investors who have been in JD Sports for a while will be haunted by last year’s disappointing Christmas figures which saw shares plummet in January and will be looking to avoid a repeat performance this year.”